These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 15765177)
21. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. Garnero P; Hausherr E; Chapuy MC; Marcelli C; Grandjean H; Muller C; Cormier C; Bréart G; Meunier PJ; Delmas PD J Bone Miner Res; 1996 Oct; 11(10):1531-8. PubMed ID: 8889854 [TBL] [Abstract][Full Text] [Related]
22. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption. Papapoulos SE; Frölich M J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849 [TBL] [Abstract][Full Text] [Related]
23. Biochemical markers of bone turnover in Paget's disease of bone. Delmas PD J Bone Miner Res; 1999 Oct; 14 Suppl 2():66-9. PubMed ID: 10510216 [TBL] [Abstract][Full Text] [Related]
24. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Meier C; Meinhardt U; Greenfield JR; De Winter J; Nguyen TV; Dunstan CR; Seibel MJ Clin Lab; 2006; 52(1-2):1-10. PubMed ID: 16506358 [TBL] [Abstract][Full Text] [Related]
25. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone. Garnero P; Christgau S; Delmas PD Bone; 2001 May; 28(5):461-4. PubMed ID: 11344044 [TBL] [Abstract][Full Text] [Related]
26. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy. Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143 [TBL] [Abstract][Full Text] [Related]
27. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438 [TBL] [Abstract][Full Text] [Related]
28. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. Okabe R; Inaba M; Nakatsuka K; Miki T; Naka H; Moriguchi A; Nishizawa Y J Bone Miner Metab; 2004; 22(2):127-31. PubMed ID: 14999523 [TBL] [Abstract][Full Text] [Related]
29. A new monoclonal antibody ELISA for detection and characterization of C-telopeptide fragments of type I collagen in urine. Srivastava AK; MacFarlane G; Srivastava VP; Mohan S; Baylink DJ Calcif Tissue Int; 2001 Dec; 69(6):327-36. PubMed ID: 11800229 [TBL] [Abstract][Full Text] [Related]
30. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538 [TBL] [Abstract][Full Text] [Related]
31. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593 [TBL] [Abstract][Full Text] [Related]
32. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg. Abelson A Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324 [TBL] [Abstract][Full Text] [Related]
33. Increased cartilage type II collagen degradation in patients with osteogenesis imperfecta used as a human model of bone type I collagen alterations. Rousseau JC; Chevrel G; Schott AM; Garnero P Bone; 2010 Apr; 46(4):897-900. PubMed ID: 20005316 [TBL] [Abstract][Full Text] [Related]
34. Cross-sectional evaluation of bone metabolism in men. Szulc P; Garnero P; Munoz F; Marchand F; Delmas PD J Bone Miner Res; 2001 Sep; 16(9):1642-50. PubMed ID: 11547833 [TBL] [Abstract][Full Text] [Related]
35. Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement. Peris P; Alvarez L; Vidal S; Kasper D; Leeming DJ; Monegal A; Angeles Martínez M; Pons F; Guañabens N Calcif Tissue Int; 2006 Jul; 79(1):22-6. PubMed ID: 16868670 [TBL] [Abstract][Full Text] [Related]
36. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. Allanore Y; Borderie D; Lemaréchal H; Cherruau B; Ekindjian OG; Kahan A J Rheumatol; 2003 Jan; 30(1):68-73. PubMed ID: 12508392 [TBL] [Abstract][Full Text] [Related]
37. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity. Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934 [TBL] [Abstract][Full Text] [Related]
38. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer. Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784 [TBL] [Abstract][Full Text] [Related]
39. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381 [TBL] [Abstract][Full Text] [Related]
40. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women. Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]